BPT958 / Bright Peak Therap - LARVOL DELTA

Bright Peak Therapeutics Presents New Data at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) - "In vitro, masked BPT958 is inactive in the absence of PD-1 expression. In contrast, in PD1HIGH cells, BPT958 exhibits moderate potency due to cis-signaling which is further enhanced following protease-mediated activation; In mice, PD1-IL2TAP exhibits an Ab-like PK profile characterized by a long plasma half-life and sustained high exposure within the TME; BPT958 shows minor activity on NK and CD8+ T cells in the periphery while inducing a significant expansion of CD8+ Teff cells in the TME; In vivo, BPT958 exhibits a superior safety profile compared to non-masked PD1-IL2 translating into an increased therapeutic window in PD-1-sensitive as well PD-1-resistant tumor models."

Preclinical • Oncology